Prognostic role of CD4 T-cell depletion after frontline fludarabine, cyclophosphamide and rituximab in chronic lymphocytic leukaemia

BACKGROUND: Eradication of minimal residual disease (MRD), at the end of Fludarabine-Cyclophosphamide-Rituximab (FCR) treatment, is a validated surrogate marker for progression-free and overall survival in chronic lymphocytic leukaemia. But such deep responses are also associated with severe immuno-...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:BMC Cancer
Hlavní autoři: Gauthier, Martin, Durrieu, Françoise, Martin, Elodie, Peres, Michael, Vergez, François, Filleron, Thomas, Obéric, Lucie, Bijou, Fontanet, Quillet Mary, Anne, Ysebaert, Loic
Médium: Artigo
Jazyk:Inglês
Vydáno: BioMed Central 2019
Témata:
Research Article
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC6694602/
https://ncbi.nlm.nih.gov/pubmed/31412798
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12885-019-5971-z
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky